Seagen Announces U.S. FDA Approval of New Indication for Adcetris (brentuximab vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma
Approval Based on Phase 3 Clinical Study That Demonstrated a 59% Reduction in Risk of Disease Progression or Relapse, Second Malignancy or Death vs. Standard of Care
BOTHELL, Wash.--(BUSINESS WIRE) November 10, 2022 --Seagen Inc. (Nasdaq: SGEN)...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Cancer & Oncology | Children | Drugs & Pharmacology | Hodgkin's Disease | Lymphoma | Study